abstract |
The present invention is an inhibitor of imidazo [1,2-b] [1,2,4] triazine and imidazo [1,2-a] pyrimidine, and kinases such as c-Met, cancer and kinase pathways The present invention relates to a pharmaceutical composition useful for the treatment of other diseases associated with dysregulation. |